NAD+ is not a peptide — what that changes

NAD+ identity data

Why the vials are so much larger

A research peptide vial holds 5 or 10 mg. These hold 500 to 1000 mg — two orders of magnitude more material. The difference is not a difference in potency but in what the compound is: a coenzyme used stoichiometrically in biochemical assays rather than a signalling peptide active at low concentration.

A 500 mg vial in 10 mL gives 50 mg/mL, which at 663.43 g/mol is about 75 mM. That is a working stock concentration in the range biochemical assay protocols are usually written for.

A redox cofactor, which is a different kind of molecule entirely

NAD+ is a hydride acceptor. It cycles between an oxidised form and a reduced form, NADH, carrying electrons between reactions — which is why it appears in the equations for glycolysis, the citric acid cycle and oxidative phosphorylation. It is not a signalling molecule that binds a receptor; it is a substrate that biochemistry consumes and regenerates.

That is why the vials are two orders of magnitude larger than a peptide vial. A signalling peptide acts at low concentration on a receptor. A cofactor participates stoichiometrically in reactions, so the amounts involved in laboratory work are correspondingly larger.

The enzymes that consume it rather than recycle it

Alongside the redox cycling, several enzyme families use NAD+ as a consumed substrate rather than a recycled carrier — sirtuins, PARPs and CD38 among them. Those reactions cleave the molecule rather than returning it, which is the basis for the research interest in cellular NAD+ availability.

For a researcher the practical consequence is that this compound sits in two different literatures at once: classical bioenergetics, where it is a carrier, and the more recent work on the consuming enzymes. Papers from the two do not always mean the same thing by a concentration figure.

Why analytical conventions differ from peptides

The oxidised and reduced forms are different compounds with different masses and different UV spectra, and the ratio between them is itself a measurement in many experiments. A Certificate of Analysis should be explicit about which form is supplied — an ambiguity that has no equivalent in a peptide COA, where there is only one molecule to report.

Peptide COA conventions do not transfer

• ◆There is no sequence to confirm, so the identity check is the mass and, where offered, the UV absorbance ratio rather than a sequence match.
• ◆Amino acid analysis is meaningless here. The peptide-content correction that matters so much for peptides has no equivalent, though water content still does.
• ◆Purity is normally reported by HPLC against a reference standard, and the meaningful impurities are hydrolysis and reduction products rather than deletion sequences.
• ◆The oxidised form NAD+ and the reduced form NADH are different compounds with different masses and different UV spectra. A COA should be explicit about which is in the vial.

Stability in solution

In aqueous solution the compound hydrolyses, and the rate is strongly pH-dependent — it is markedly less stable in alkaline conditions than near neutral. Where a reconstituted peptide might be workable for weeks refrigerated, solutions of this compound are generally prepared closer to the time of use.

Frozen aliquots are the standard approach for the same reason they are for peptides, and the same freeze-thaw caution applies: aliquot before the first freeze rather than re-freezing a single vial.

Naming

NAD+, NADH, NMN and NR are related but distinct compounds with different CAS numbers and different molecular weights. Suppliers sometimes use the names loosely. Checking the CAS number against the one above is the fastest way to confirm which compound is actually being offered.